Extraordinary times

“Extraordinary times call for extraordinary measures.” — Benet Wilson

Last month’s U.S. Medicine August 2020 editorial, “It feels like writing ‘Bad things are about to happen’ on a napkin and then setting the napkin on fire.” — Colin Carlson, was angry. This month’s editorial is an admission of regret for that anger, a recognition that anger serves no useful purpose in the face of national tragedy. It perhaps defines a better way to act going forward. Admittedly, the editorial was cathartic for me. Still, I am not sure it was much of a public service to my readers. The depth and breadth of the COVID-19 pandemic in this country has been overwhelming to society. It has exposed divisions in our union that have been simmering under our national veneer of unity.

Surveillance, Barriers to Care Key to Federal Medicine Fight Against HCC

Mortality rates from most cancers have declined in recent years, but deaths from hepatocellular carcinoma continue to climb. Both the VA and the DoD are moving aggressively to detect and treat liver disease before it progresses to hepatocellular carcinoma (HCC) and to quickly identify patients who have developed this devastating disease.

AGA’s New Advice on Screening for NAFLD and Hepatocellular Carcinoma

The association between NAFLD cirrhosis and HCC is well-established, and most experts believe that screening should be recommended in this setting. The decision to enter a patient into a screening program for HCC is determined by the level of risk for HCC, while also taking into account the patient’s age, overall health, functional status, and willingness and ability to comply with screening assessment.

Houston, Miami VAMCs Participate in Tocilizumab Trial

HOUSTON—The Michael E. DeBakey VAMC in Houston and the Bruce W. Carter VAMC in Miami are among nearly 70 locations across the world participating in a randomized double-blind clinical trial of an immunomodulator, tocilizumab, for patients with severe pneumonia...